New interventions for obstructive hypertrophic cardiomyopathy: Promise and prudence

European Heart Journal

Volumn 20, Issue 18, 1999, Pages 1292-1294

  Maron, B J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

ALCOHOL SEPTAL ABLATION; CATHETER ABLATION; EDITORIAL; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MYOTOMY; PRIORITY JOURNAL;

EID: 0032846522     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1666     Document Type: Editorial

References (6)

1. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997; 350: 127-33.
2. Gietzen FH, Leuner ChJ, Raute-Kreinsen U et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic cardiomyopathy. Eur Heart J 1999; 20: 1342-54.
3. Knight C, Kurbaan AS, Seggewiss H. et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Outcome in the first series of patients. Circulation 1997; 95: 2075-81.
4. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 30 month follow-up in 25 patients. J Am Coll Cardiol 1993; 31: 252-8.
5. Lakkis NM, Nagueh SF, Kleiman NS et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-5.
6. Spirito P, Maron BJ.Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 33: 1071-5.